Cancer Advances
Durham, United States (US) · Health and Medical
Do you work at Cancer Advances?
Claim this profile to manage your company.
Verified by Enterprise League
Data quality
Complete · Accuracy
Cancer Advances is a Durham, North Carolina-based biotechnology company focused on developing novel cancer therapeutics.We are dedicated to pioneering new medicines and redefining possibilities for cancer patients through the development of PAS (Polyclonal Antibody Stimulator), a vaccine designed to stimulate the immune system to produce endogenous polyclonal antibodies against gastrin, offering a safer alternative to traditional therapies.Our core expertise lies in leveraging intellectual property acquired from Aphton Corporation and Receptor Biologix, built upon research originating from the University of Nottingham.
Overview
We are dedicated to pioneering new medicines and redefining possibilities for cancer patients through the development of PAS (Polyclonal Antibody Stimulator), a vaccine designed to stimulate the immune system to produce endogenous polyclonal antibodies against gastrin, offering a safer alternative to traditional therapies.
Our core expertise lies in leveraging intellectual property acquired from Aphton Corporation and Receptor Biologix, built upon research originating from the University of Nottingham. We are currently exploring synergies between PAS and other treatment classes to enhance patient outcomes.
Cancer Advances holds over 100 patents related to PAS and actively pursues a robust trademark strategy, solidifying our position as a leader in innovative cancer vaccine development.
Contact Details
Durham, United States (US), 4364 S Alston Ave
Founded
2008
Company Type
Private Limited Company
Employees
10-20
Categories
Companies teams usually look at after Cancer Advances
Comparing a few options usually leads to better decisions
Save companies to compare later. Useful when sharing options with your team
This is how your company profile looks to others.